This high-flying biotech stock is taking a breather. Time to buy?
News & Analysis: Amarin
The stock rose in anticipation of a business update at the end of the month.
Vascepa could become a top-selling medication. Here's why.
AMRN earnings call for the period ending December 31, 2018.
Amarin and Aphria could both be bought out soon.
The Irish biotech company's stock started 2019 off with a bang thanks to two catalysts.
Find out why some aren't nearly as enthusiastic about the future for these two biotech stocks.
A Pfizer buyout of Amarin is still just a rumor. But rumors sometimes turn into reality.
The Irish biotech company's stock has been on fire for two related reasons.
These biotech stocks jumped 31% or more over the last few days. Can their momentum continue?